Haematologica, Vol 92, Issue 2, 273-274 doi:10.3324/haematol.10595
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choquet, S.
Right arrow Articles by Oertel, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choquet, S.
Right arrow Articles by Oertel, S.

Malignant Lymphomas

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation

Sylvain Choquet*, Ralf Trappe*,, Veronique Leblond*, Ulrich Jäger#, Frederic Davi*, Stephan Oertel°

* Department of Haematology, Hôpital Pitié-Salpétrière, Paris, France
° Department of Hematology and Oncology, Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany
# Department of Hematology and Haemostaseology, AKH, Wien, Austria

Correspondence: Ralf Ulrich Trappe, Deutsche Studiengruppe Posttransplantationslymphome, Charité, Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Augustenburger Platz 1, 13353 Berlin, Germany. Phone: international +49.030.450553510. Fax: international + 49.030.450553901, E-mail: ralf.trappe{at}charite.de

There is no definitive treatment for post-transplant lymphoproliferative disorder (PTLD) that does not respond to reduction of immunosuppression. With a median follow-up of 8.8 years, the current retrospective analysis of standard CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) in 26 adults with PTLD demonstrated an overall response rate of 65% and median overall and progression-free survivals of 13.9 and 42 months, respectively.

Key words: post-transplant lymphoproliferative disorder, immunosuppression, chemotherapy, CHOP, rituximab.




This article has been cited by other articles:


Home page
 BloodHome page
H. E. Heslop
How I treat EBV lymphoproliferation
Blood, November 5, 2009; 114(19): 4002 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Knight, A. Tsodikov, D. M. Cibrik, C. W. Ross, M. S. Kaminski, and D. W. Blayney
Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center
J. Clin. Oncol., July 10, 2009; 27(20): 3354 - 3362.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Y. Zafar, D. N. Howell, and J. P. Gockerman
Malignancy After Solid Organ Transplantation: An Overview
Oncologist, July 1, 2008; 13(7): 769 - 778.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Carbone, A. Gloghini, and G. Dotti
EBV-Associated Lymphoproliferative Disorders: Classification and Treatment
Oncologist, May 1, 2008; 13(5): 577 - 585.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J.-J. Lee, M. S. Lam, and A. Rosenberg
Role of Chemotherapy and Rituximab for Treatment of Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation
Ann. Pharmacother., October 1, 2007; 41(10): 1648 - 1659.
[Abstract] [Full Text] [PDF]